Kaletra (Lopinavir/Ritonavir)
| Brand Name: |
Kaletra |
| Generic Name: |
Lopinavir/Ritonavir, LPV/RTV |
| Adult Single Dose*: |
400/100 mg (two 200/50-mg tablets or 5-mL oral solution) twice daily |
| Food & Liquid Restrictions: |
Oral solution must be taken with food. Tablets can be taken with or without food. Side effects may be lessened with food. |
| Drug Class: |
PI |
| * This recommendation is for patients starting HIV treatment. A different dose is recommended for treatment experienced patients. |
The Basics
- Lopinavir + Ritonavir (Kaletra) (November 30, 2012)
To read PDF, click here.
From AIDS InfoNet
- An Overview of Kaletra (Lopinavir/Ritonavir) (September 13, 2012)
From AIDSinfo
- Kaletra (March/April 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- FAQs About Kaletra (Lopinavir/Ritonavir) (January 12, 2012)
From The Body's "Ask the Experts" Forums
- Medication Guide for Kaletra (February 2011)
Created by the makers of Kaletra specifically for people with HIV. Includes a rundown of possible side effects, reasons why Kaletra may not be a good fit for everybody, meds to avoid while taking Kaletra, and tips on how to maximize the chances Kaletra will work well.
From Abbott Laboratories
- Patient Information About Kaletra (Lopinavir/Ritonavir) Tablets and Oral Solution (PDF) (February 2011)
From Abbott Laboratories
- Patient Frequently Asked Questions (2011)
Information about the new Kaletra (lopinavir/ritonavir) tablets.
From Abbott Laboratories
- Kaletra (Lopinavir/Ritonavir) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- Lopinavir (Kaletra) (August 15, 2006)
From AIDS Treatment Data Network
- Kaletra (Lopinavir/Ritonavir) (November 2005)
To read PDF, click here.
From The Center for AIDS
VIEW ALL ARTICLES
News
- Abbott Cuts Cost of AIDS Drug for Government Programs (May 10, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Abbott Cuts Cost of AIDS Drug for Government Programs (April 29, 2011)
In Chicago Tribune
- Lopinavir/r Oral Solution (March/April 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- U.S. Jury Rejects Glaxo Antitrust Claim vs. Abbott (March 31, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- U.S. Warns Against Abbott HIV Drug in Premature Babies (March 9, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Kaletra (Lopinavir/Ritonavir) Oral Solution Label Changes Related to Toxicity in Preterm Neonates (February 24, 2011)
From U.S. Food and Drug Administration
- Once a Day Kaletra Gets Approved for Treatment Experienced, but With Caution (February 2011)
To read PDF, click here.
In Project Inform Perspective, from Project Inform
- Indian Government Rejects Abbott's Patent Application for Second-Line ARV (January 4, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Lopinavir/Ritonavir Approved (Summer/Fall 2010)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- FDA Probes Risks of HIV, Prostate, Other Drugs (May 4, 2010)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
VIEW ALL ARTICLES
Research
 Pharmacokinetics and Acceptability of Lopinavir/Ritonavir Sprinkles in Children Aged 1 to 4 Years (March/April 2013)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Lopinavir/Ritonavir Equivalent to Nevirapine in Ugandan Children (March 14, 2013)
From aidsmap.com
- HIV Drug Not Tied to Premature Births (March 8, 2013)
From MedPage Today
- Lopinavir/Ritonavir in Pregnancy: Results From a Systematic Review (January/February 2013)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Simplified Protease Inhibitor Monotherapy Fails to Maintain HIV Suppression (October 26, 2012)
From HIVandHepatitis.com
- Simplifying HAART Regimen Fails to Maintain HIV-1 Viral Suppression (October 23, 2012)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
On TheBodyPRO.com
- Novel Lopinavir/Ritonavir Sprinkle Formulation for Children in Resource-Limited Settings (July/August 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Lopinavir/Ritonavir Monotherapy in Children (March/April 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Lower Malaria Risk in Children Receiving Lopinavir/Ritonavir-Based Compared to NNRTI-Based ART (March/April 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- ARV Given to HIV-Positive Children Boosts Preventive Power of Key Malaria Drug, Study Shows (March 15, 2012)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
On TheBodyPRO.com
VIEW ALL ARTICLES
|
|
Advertisement
|
Email
Glossary
